Titlebook: Vaccine Design; The Role of Cytokine Gregory Gregoriadis,Brenda McCormack,Anthony C. Al Book 1997 Springer Science+Business Media New York

西瓜

Active Immunotherapy for Solid Tumours, effort has started to be made to prove or disprove the possibility that “therapeutic vaccines” may have more than just anecdotal efficacy against cancer. The recognition that the immune system could be stimulated into rejecting established tumour came from the work of Coley (1893/1894) who refined

從屬

蹣跚

啞劇

,Interleukin 1 and Its Synthetic Peptide 163–171 as Vaccine Adjuvants, immune and inflammatory reactions (Dinarello, 1991; Boraschi and Tagliabue, 1989). The IL-1 family includes IL-1α and IL-1γ, which have similar structures and overlapping biological activities, and IL-1ra, which is a pure receptor antagonist, able to occupy the activating IL-1 receptor (IL-1R.) wit

Iatrogenic

The Immunological Co-Adjuvant Action of Liposomal Interleukin-15,terleukin-2 (IL-2) (Tan and Gregoriadis, 1989; Ho et al, 1992; Abraham and Shah, 1992; Sencer et al, 1991; Mbawuike et al, 1990; Anderson et al, 1994; Gursel and Gregoriadis, 1997a). It has been suggested (Meuer et al, 1989) that the co-adjuvant activity of liposomal IL-2 could prove useful in the v

Ligament

Protection Against Tuberculosis by Plasmid DNA,mycobacterial protein antigens can be tested for their ability to confer protective immunity. Expression of protection against mycobacteria is largely a function of antigen specific CD4 and cytotoxic CD8 T cells. We have found that intramuscular injection of plasmid DNA expressing several mycobacter

記憶法

tariff

Protection Against Tuberculosis by Plasmid DNA, a function of antigen specific CD4 and cytotoxic CD8 T cells. We have found that intramuscular injection of plasmid DNA expressing several mycobacterial immunodominant genes can induce both T cell populations and confer protection equivalent to BCG, suggesting that this approach may lead to a new vaccine.

ELUC

Traumatic-Grief